ACPE Universal
Program Number: 207-000-06-165-H01
Release Date: December 15, 2006
Expiration Date: December 15, 2009
Description
Pancreatic extract drug products are indicated in the treatment
of exocrine pancreatic insufficiency, which is a potential complicating
factor in cystic fibrosis, chronic pancreatitis, pancreatic tumors,
or pancreatectomy. Pancreatic extract drug products, long marketed
in the United States, have a broad range of dosages and delivery
mechanisms. The FDA evaluated the safety and effectiveness of
these drug products and based on a review of all available data,
including the studies and adverse event reports the FDA concluded
that the safe and effective use of pancreatic enzyme drug products
requires that the products be marketed by prescription only and
that the products be approved through the new drug approval process
to standardize enzyme activity. The FDA determined that bioactivity
must be shown to correlate with the stated potency of each product,
particularly for newer formulations that include microspheres
and high-potency levels of pancreatic enzymes, which underlines
the importance of consistent drug therapy in the class of pancreatic
enzymes and the difficulties the pharmacist must be aware of in
generic substitution and therapeutic interchange.
Instructions for Participation
To receive a certificate of completion that indicates your eligibility for continuing education credit, you must:
- Review
the content of the activity.
- Successfully complete the post-test (70% or higher).
- You will have
two (2) opportunities to successfully complete the activity.
Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.
Fee
There is no fee for this activity.
Accreditation
Pharmacists
NCPA
is approved by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education. This program will
provide 2.0 contact hours (.2 CEUs) of continuing pharmacy education
credit under the number 207-000-06-165-H01.
Faculty
Gary Milavetz,
B.S., Pharm.D.
Associate Professor of Pharmacy
Division of Clinical and Administrative Pharmacy
College of Pharmacy
University of Iowa
Mary E. Teresi, B.S., Pharm.D.
Director of Clinical Trials
Pediatric Allergy and Pulmonary Division
Department of Pediatrics
University of Iowa Hospitals and Clinics
Maria Osterhaus
Doctor of Pharmacy Candidate
College of Pharmacy
University of Iowa
Disclosure
Declaration
It is the policy of the National Community Pharmacists
Association (NCPA) to ensure independence, balance, objectivity,
scientific rigor, and integrity in all of their continuing education
activities.
The author,
sponsor, and publisher of this continuing education activity have
made all reasonable efforts to ensure that information contained
herein is accurate in accordance with the latest available scientific
knowledge at the time of accreditation of this continuing education
program. Information regarding drugs (e.g., their administration,
dosages, contraindications, adverse reactions, interactions, special
warnings, precautions) and drug delivery systems are subject to
change, however, and the reader is advised to check the manufacturer's
package insert for information concerning recommended dosage and
potential problems or cautions prior to dispensing or administering
the drug or using the drug delivery systems.
Approval of credit for this continuing education activity does not
imply endorsement by NCPA of any product or manufacturer identified.
Any medications or treatment methods suggested in this CE activity
should not be used by the practitioner without evaluation of their
patient's condition(s) and possible contraindication(s) or danger(s)
of use of any specific medication.
Commercial
Support
Commercial Support Provided by Solvay Pharmaceuticals,
Inc.
Software
Requirements